



AT THE FOREFRONT
**UChicago
Medicine**



THIRD ANNUAL

Cholangiocarcinoma Regional Symposium

OCTOBER 5, 2022 | KNAPP CENTER FOR BIOMEDICAL DISCOVERY



CONFERENCE DIRECTORS

UChicago Medicine
John Fung, MD, PhD
Anjana Pillai, MD

Cholangiocarcinoma Foundation
Melinda Bachini
Lisa Craine



Third Annual Cholangiocarcinoma Regional Symposium

October 5, 2022 | Knapp Center for Biomedical Discovery, 900 E. 57th St., Chicago, IL 60637

Course Description

Cholangiocarcinoma (CCA) or bile duct cancer is the second most common cause of primary liver cancer and its incidence continues to rise worldwide.

There has been a shift in incidence to younger populations and those without any traditional risk factors for bile duct cancer. Because CCA can have varying etiologies and a heterogeneous clinical presentation, treatment options vary based on anatomical disease location and extent of disease (or spread). Through advances in medical, surgical and locoregional therapy options, there has been a paradigm shift in the treatment landscape with patients living longer, fuller lives. Multidisciplinary care remains the best way to provide individualized patient care for optimal outcomes.

This interactive symposium will include presentations from members of the University of Chicago Medicine Liver Tumor Program and notable faculty in the field of cholangiocarcinoma. Invited faculty will present up-to-date information on systemic therapy, surgical options including liver transplant and locoregional therapy. We also have a special multidisciplinary tumor board and patient and caregiver perspective this year.



Third Annual Cholangiocarcinoma Regional Symposium

October 5, 2022 | Knapp Center for Biomedical Discovery, 900 E. 57th St., Chicago, IL 60637

Course Faculty

COURSE DIRECTORS



John Fung MD, PhD

With more than 30 years of experience, Dr. John Fung is an international leader in the field of organ transplantation, including liver, kidney, pancreas, islet and intestinal transplantation. Dr. Fung

is the chief of transplant surgery and the co-director of the Transplant Institute. Dr. Fung has spearheaded the use of new minimally invasive surgical transplant techniques. Additionally, he's an accomplished immunologist and has introduced procedures to improve donor organ preservation. Dr. Fung has a long-standing research interest in transplantation immunology, immunosuppression therapy and liver-related immunology. He has published more than 1,000 articles and book chapters and has helped to spearhead the transplant oncology program at UChicago Medicine with his colleagues from the Liver Tumor Program.



Anjana Pillai, MD

Dr. Anjana Pillai is the associate professor of medicine, the medical director of the Liver Tumor Program, which encompasses multiple specialists with expertise in benign and malignant

tumors of the liver, and the co-director of the Living Donor Liver Transplant Program. Dr. Pillai is a transplant hepatologist who specializes in the management of chronic liver disease and liver transplantation. Dr. Pillai is also an active researcher with a focus on hepatobiliary malignancies, including hepatocellular carcinoma and cholangiocarcinoma. As part of the University of Chicago Medicine Comprehensive Cancer Center, she works to provide individualized treatment options to her patients. She and her colleagues in the Liver Tumor Program have spearheaded the transplant oncology program at UChicago Medicine.

GUEST SPEAKER



Rachna T Shroff, MD, MS

Dr. Rachna T. Shroff is an Associate Professor of Medicine and Chief of GI Medical Oncology as well as Leader of the Gastrointestinal Clinical Research Team at the University of Arizona Cancer Center. She is the Director of the UArizona Cancer Center Clinical Trials Office as well as the Director of the Arizona Clinical Trials Network (ACTN), and Vice Chair of Clinical Research for the Department of Medicine. Dr. Shroff is a clinical and translational investigator focused on developing novel therapies for pancreatic and biliary cancers. She holds multiple positions nationally due to her expertise

in these areas, including serving as the Hepatobiliary subcommittee Co-Chair for the Southwest Oncology Group (SWOG). She is a member of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation.



Third Annual Cholangiocarcinoma Regional Symposium

October 5, 2022 | Knapp Center for Biomedical Discovery, 900 E. 57th St., Chicago, IL 60637

Course Faculty

CLINICIAN SPEAKERS



Osman Ahmed, MD

Associate Professor of Radiology


Dr. Osman Ahmed is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants Inferior Vena Cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage.



Diego di Sabato, MD

Assistant Professor of Surgery

Dr. Diego di Sabato is an expert liver and kidney transplant surgeon who specializes in living donor transplantation, providing his patients with an alternative to waiting for a deceased-donor organ. As a Spanish-speaking transplant surgeon, Dr. di Sabato is dedicated to helping Hispanic and Latinx patients and families who seek the highest quality transplant care. Dr. di Sabato diagnoses, manages and treats a wide range of liver and kidney diseases, and has expertise in treating benign and malignant hepatobiliary tumors as part of the multidisciplinary Liver Tumor Program.



Andy Liao, MD

Assistant Professor of Medicine

Dr. Chih-Yi “Andy” Liao is a medical oncologist and expert on bile duct cancer, advanced thyroid cancer, and gastrointestinal neuroendocrine tumors (GI-NETs) stemming from the hormonal and nervous systems. A member of the University of Chicago Medicine’s renowned gastrointestinal oncology team, Dr. Liao also is part of the multidisciplinary Liver Tumor Program. As a clinical investigator, Dr. Liao develops and conducts clinical trials to evaluate targeted therapies and immunotherapies for bile duct cancers and GI-NETs.



Third Annual Cholangiocarcinoma Regional Symposium

October 5, 2022 | Knapp Center for Biomedical Discovery, 900 E. 57th St., Chicago, IL 60637

Course Faculty

CLINICIAN SPEAKERS



Namrata Setia, MD

Associate Professor of Pathology

Dr. Namrata Setia is a surgical pathologist with a subspecialty focus on gastrointestinal pathology. Her research and scholarly interests include neoplastic and non-neoplastic diseases of stomach and hereditary diseases of the gastrointestinal tract.



Elizabeth Holohan, MSN, RN

Elizabeth Holohan is the lead liver tumor and living donor nurse coordinator for UChicago Medicine's Transplant Institute. She brings over seven years of clinical experience working with transplant patients in a variety of settings including the operating room, ICU, and for the last three years, the outpatient clinics. As part of this team, she strives to provide individualized and compassionate care to all of her patients as she guides them through their complex medical journeys. She plays an integral role in patient advocacy and supports the growth and development of the Liver Tumor Program.



Third Annual Cholangiocarcinoma Regional Symposium

October 5, 2022 | Knapp Center for Biomedical Discovery, 900 E. 57th St., Chicago, IL 60637

Conference Agenda *Wednesday, October 5, 2022*

8 a.m.	Check-in begins
8-9 a.m.	Coffee/light breakfast snacks
9-9:10 a.m.	Welcome and Intro Lisa Craine and John Fung, MD, PhD
9:10-9:30 a.m.	Overview of Cholangiocarcinoma Foundation Melinda Bachini, CCF
SESSION 1 Systemic Therapy Updates in CCA Moderator: John Fung, MD, PhD	
9:30-9:50 a.m.	Overview of systemic therapy landscape Andy Liao, MD
9:50-10:10 a.m.	Targeted therapies and immunotherapy Rachna Schroff, MD, MS
10:10-10:30 a.m.	Molecular Profiling in CCA Namrata Setia, MD
10:30-11 a.m.	Panel Q&A Namrata Setia, MD, Andy Liao, MD, and Rachna Shroff, MD, MS
11-11:15 a.m.	BREAK (light refreshments)
SESSION 2 Evolution of Non-Systemic Therapies in CCA Moderator: Anjana Pillai, MD	
11:15-11:35 a.m.	Update on LT in CCA Anjana Pillai, MD
11:35-11:55 a.m.	Evolution of living donor transplant for CCA John Fung, MD, PhD
11:55 a.m.-12:15 p.m.	Locoregional therapy in the treatment of CCA Osman Ahmed, MD
12:15-12:45 p.m.	Panel Q&A Anjana Pillai, MD, John Fung, MD, PhD, and Osman Ahmed, MD
12:45-1:30 p.m.	LUNCH BREAK
SESSION 3 Moderator: Andy Liao, MD	
1:30-2:15 p.m.	Multidisciplinary tumor board Diego di Sabato, MD, Anjana Pillai, MD, Osman Ahmed, MD, and Elizabeth Holohan, MSN, RN
2:15-2:45 p.m.	Karl, Diana, and Robert Torchalski with caregiver experience
2:45-3 p.m.	Closing remarks John Fung, MD, PhD, and Anjana Pillai, MD

A recording of this program will be available after the symposium on the Cholangiocarcinoma Foundation's website and YouTube channel.



AT THE FOREFRONT

**UChicago
Medicine**

UChicago Medicine Liver Tumor Program

The University of Chicago Medicine's comprehensive Liver Tumor Program brings together the multidisciplinary expertise needed to personalize the best treatment options for our patients.

A collaborative effort between experts from multiple specialties, our program offers comprehensive and detailed evaluation of patients. Our experts are equipped to manage complex cases, offering hope for those who have not been considered previously for curative options. We see patients with early and advanced-stage disease. Patients at our clinic receive access to novel treatment options, including the latest clinical trials of promising therapies.

Every case is unique, and we aim to provide your patients with individualized treatment plans tailored to their specific needs. In many cases, we offer our patients the ability to see multiple consultants in one day, thus eliminating the need for repeated trips to the hospital.

Cholangiocarcinoma Foundation

The Cholangiocarcinoma Foundation's (CCF) mission is to find a cure and improve the quality of life for those affected by cholangiocarcinoma (bile duct cancer).

Founded in 2006, in Salt Lake City, Utah, by a family who lost a loved one to cholangiocarcinoma, CCF has grown to become the leading global resource in research, education, and public awareness.

